Daxor Director Awarded 2,500 Stock Options at $9.29 Exercise Price
Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29.
Rhea-AI Filing Summary
Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan.
The options vest in three tranches—833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027—and expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 2,500 | $0.00 | $0.00 |
Footnotes (2)
- F1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
- F2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
FAQ
What insider transaction did DXR report on 29 June 2025?
When do the newly awarded DXR options vest?
Are there any conditions attached to Feuer’s DXR option grant?
What is the expiration date of the granted DXR options?
AI-generated analysis. How Rhea-AI works. Not financial advice.